On solid-phase antibody assays.
There is considerable evidence that pre-operative and post-operative anti-human leukocyte antigen (anti-HLA) antibodies are deleterious in thoracic transplantation. While debate continues in heart and lung transplantation on the role of and the diagnosis and treatment of antibody-mediated rejection (AMR), central to the discussion is our ability to detect anti-HLA antibodies. This perspective outlines the concerns elicited by new technology for detection of anti-HLA antibodies using solid-phase assays, and highlights the need for functional assays to further understand the clinical significance of these antibodies.
Pajaro
Octavio E
OE
Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1530 3rd Avenue S., Birmingham, AL, USA. opajaro@uab.edu
George
James F
JF
D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D006084:Graft Rejection / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D006650:Histocompatibility Testing / Q000379:methods*; D006801:Humans; D016040:Lung Transplantation / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D006680:HLA Antigens